Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ahsan, Nuzhat ^a   Mishra, Satyendra ^c   Jain, Manish Kumar ^b   Surolia, Avadhesha ^c   Gupta, Sarika ^a  

^a NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

^c INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CURCUMIN; PROTEIN AGGREGATE; PROTEIN BINDING;

ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; CHEMISTRY; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; KINETICS; METABOLISM; MUTATION; PATHOLOGY; PROTEIN MULTIMERIZATION; PROTEINOSIS; STRUCTURE ACTIVITY RELATION;

ALPHA-SYNUCLEIN; CURCUMIN; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KINETICS; MODELS, BIOLOGICAL; MUTATION; NEURODEGENERATIVE DISEASES; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; PROTEIN MULTIMERIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84929590569     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09862     Document Type: Article

References (42)

1. Moreno-Gonzalez, I. & Soto, C. Misfolded protein aggregates: mechanisms, structures and potential for disease transmission. Semin Cell Dev Biol 22, 482-7 (2011).
2. Stefanova, N., Bucke, P., Duerr, S. & Wenning, G. K. Multiple system atrophy: an update. Lancet Neurol 8, 1172-8 (2009).
3. Jellinger, K. A. Neuropathological spectrum of synucleinopathies. Mov Disord 18 Suppl 6, S2-12 (2003).
4. George, S., Rey, N. L., Reichenbach, N., Steiner, J. A. & Brundin, P. alpha-Synuclein: the long distance runner. Brain Pathol 23, 350-7 (2013).
5. Marques, O. & Outeiro, T. F. Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3, e350 (2012).
6. Bayer, T. A. et al. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease betaamyloid plaque cores. Neurosci Lett 266, 213-6 (1999).
7. Uversky, V. N. & Eliezer, D. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein. Curr Protein Pept Sci 10, 483-99 (2009).
8. Volles, M. J. et al. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-9 (2001).
9. Pieri, L., Madiona, K., Bousset, L. & Melki, R. Fibrillar alpha-synuclein and huntingtin exon 1 assemblies are toxic to the cells. Biophys J 102, 2894-905 (2012).
10. Lashuel, H. A. et al. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322, 1089-102 (2002).
11. Li, J., Zhu, M., Rajamani, S., Uversky, V. N. & Fink, A. L. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11, 1513-21 (2004).
12. Cheng, B. et al. Inhibiting toxic aggregation of amyloidogenic proteins: a therapeutic strategy for protein misfolding diseases. Biochim Biophys Acta 1830, 4860-71 (2013).
13. Rigacci, S. et al. Abeta (1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. Curr Alzheimer Res 8, 841-52 (2011).
14. Garcia-Alloza, M., Borrelli, L. A., Rozkalne, A., Hyman, B. T. & Bacskai, B. J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102, 1095-104 (2007).
15. Ringman, J. M., Frautschy, S. A., Cole, G. M., Masterman, D. L. & Cummings, J. L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res 2, 131-6 (2005).
16. Qiu, X. et al. Synthesis and identification of new 4-arylidene curcumin analogues as potential anticancer agents targeting nuclear factor-kappaB signaling pathway. J Med Chem 53, 8260-73 (2010).
17. Ferrari, E. et al. Newly synthesized curcumin derivatives: crosstalk between chemico-physical properties and biological activity. J Med Chem 54, 8066-77 (2011).
18. Zhao, C., Liu, Z. & Liang, G. Promising curcumin-based drug design: monocarbonyl analogues of curcumin (MACs). Curr Pharm Des 19, 2114-35 (2013).
19. Chakraborti, S. et al. Stable and potent analogues derived from the modification of the dicarbonyl moiety of curcumin. Biochemistry 52, 7449-60 (2013).
20. Mishra, S., Karmodiya, K., Surolia, N. & Surolia, A. Synthesis and exploration of novel curcumin analogues as anti-malarial agents. Bioorg Med Chem 16, 2894-902 (2008).
21. Selvam, C., Jachak, S. M., Thilagavathi, R. & Chakraborti, A. K. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett 15, 1793-7 (2005).
22. Narlawar, R. et al. Curcumin-derived pyrazoles and isoxazoles: Swiss army knives or blunt tools for Alzheimer's disease? ChemMedChem 3, 165-72 (2008).
23. Changtam, C., Hongmanee, P. & Suksamrarn, A. Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity. Eur J Med Chem 45, 4446-57 (2010).
24. Ono, K., Hasegawa, K., Naiki, H. & Yamada, M. Curcumin has potent antiamyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75, 742-50 (2004).
25. Hudson, S. A., Ecroyd, H., Kee, T. W. & Carver, J. A. The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J 276, 5960-72 (2009).
26. Klunk, W. E., Jacob, R. F. & Mason, R. P. Quantifying amyloid by congo red spectral shift assay. Methods Enzymol 309, 285-305 (1999).
27. Caruana, M. et al. Inhibition and disaggregation of alpha-synuclein oligomers by natural polyphenolic compounds. FEBS Lett 585, 1113-20 (2011).
28. Chakraborti, S. et al. Curcumin recognizes a unique binding site of tubulin. J Med Chem 54, 6183-96 (2011).
29. Libertini, L. J. & Small, E. W. The intrinsic tyrosine fluorescence of histone H1. Steady state and fluorescence decay studies reveal heterogeneous emission. Biophys J 47, 765-72 (1985).
30. Zhu, M., Li, J. & Fink, A. L. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem 278, 40186-97 (2003).
31. Porat, Y., Abramowitz, A. & Gazit, E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des 67, 27-37 (2006).
32. Nakagami, Y. et al. A novel beta-sheet breaker, RS-0406, reverses amyloid betainduced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 137, 676-82 (2002).
33. Yang, F. et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280, 5892-901 (2005).
34. Singh, P. K. et al. Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem Neurosci 4, 393-407 (2013).
35. Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell 149, 1048-59 (2012).
36. Tsika, E. et al. Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: implications for neurodegeneration. J Neurosci 30, 3409-18 (2010).
37. Kayed, R. et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener 2, 18 (2007).
38. Narhi, L. et al. Both familial Parkinson's disease mutations accelerate alphasynuclein aggregation. J Biol Chem 274, 9843-6 (1999).
39. Wise-Scira, O., Dunn, A., Aloglu, A. K., Sakallioglu, I. T. & Coskuner, O. Structures of the E46K mutant-type alpha-synuclein protein and impact of E46K mutation on the structures of the wild-type alpha-synuclein protein. ACS Chem Neurosci 4, 498-508 (2013).
40. Recchia, A. et al. Alpha-synuclein and Parkinson's disease. FASEB J 18, 617-26 (2004).
41. Ahmad, B. & Lapidus, L. J. Curcumin prevents aggregation in alpha-synuclein by increasing reconfiguration rate. J Biol Chem 287, 9193-9 (2012).
42. Smith, W. W. et al. Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity. Hum Mol Genet 14, 3801-11 (2005).